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Abstract
Background: An estimated 50% of patients do not take their medication as prescribed, with medication adherence
associated with adverse outcomes and higher costs of care. The Necessity-Concerns Framework identified
individual’s beliefs about their medication as playing a key role in adherence, and UK Clinical Adherence Guidelines
recommend eliciting and incorporating individual’s perceptions of their medication within the consultation. The
Beliefs about Medicines Questionnaire (BMQ) is widely used to assess medication beliefs, however, given the
condition-specific nature of some self-management regimens, it is unknown whether this tool is able to fully
capture beliefs about more complex medication regimens.
Methods: We examined the challenges of assessing medication beliefs using the BMQ in 20 people with a
complex relapsing-remitting condition recruited from community sources. Data were collected from people with
psoriasis; a patient group characterised by complex medication regimens, which include therapies that are applied
topically, phototherapy/photochemotherapy, and therapies that are administered orally or via subcutaneous or
intravenous injections. Semi-structured cognitive interviews were undertaken, with responses coded using
established schedules and analysed using Content analysis.
Results: Individual’s beliefs about their condition specific therapies were not accurately captured by the BMQ.
Medication beliefs as expressed during ‘real-time’ completion of the BMQ were underestimated, or failed to be
captured, by the corresponding scores given by participants.
There was mismatch between the terminology used in the scale and individuals perceptions of their condition and
the complexity of its management and treatment outcomes. Currently the BMQ cannot represent beliefs about
medicines underuse, even though some individuals with psoriasis viewed access to therapies as overly restrictive.
Some the BMQ items were misinterpreted in part due to ambiguous item wording or due to misreading by
participants.
Conclusions: This is the first study to identify general and condition-specific difficulties experienced by individuals
completing the BMQ in ‘real time’. The main implication of this research is the need to develop condition-specific
versions of the BMQ in order that this important instrument can capture the full range of medication beliefs in
individuals living with a complex relapsing-remitting condition. Access to condition-specific versions could
significantly increase our understanding of beliefs which facilitate or reduce medication adherence.
Keywords: Beliefs about Medicines Questionnaire, Adherence, Shared decision-making, Psoriasis, Necessity-
Concerns Framework, Cognitive Interviewing
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Background
The effectiveness of medical therapies reported in
clinical trials are usually based on atypical levels of
medication adherence. Whilst it is recognized that such
outcomes may not be replicated in ‘real world’ clinical
practice, patients need to be optimally adherent to their
medication in order to achieve the best clinical out-
comes. Adherence is defined as the extent to which the
patient’s behaviour (medication usage) matches agreed
recommendations from the clinician [1]. High levels of
adherence is a crucial component of effective self-
management for many people living with long-term con-
ditions (LTCs) and viewed as one of the key mediators
between medical practice and clinical outcomes. How-
ever adherence rates in those with LTCs are low, with
people typically taking only half of their prescribed
medication [2]. The World Health Organisation [3]
views non-adherence as an important public health
concern, with implications for treatment response [4],
mortality [5], and additional healthcare costs, including
increased number of hospital admissions and appoint-
ments, wasted resources, disease progression and need
for more aggressive medications [1, 6].
The UK National Institute for Health and Care Excel-
lence (NICE) Medicines Adherence Guidelines [7]
recognise that non-adherence can be unintentional, re-
ferring to unforeseen barriers beyond the control of the
patient, or intentional, in which the patient makes a de-
liberate decision not to follow the prescribed medication
regimen. In order to support shared medication
decision-making and adherence, they recommend that
individual’s beliefs about their condition and medication
should be appropriately elicited and incorporated by the
clinician within the consultation. This approach has
been shown to be effective in supporting medication ad-
herence [8, 9]. According to the Necessity-Concerns
Framework [10, 11], key beliefs that influence medica-
tion adherence are perceptions of personal need for
medication for current and future health (necessity be-
liefs) and concerns about potential negative conse-
quences. The Beliefs about Medicines Questionnaire
(BMQ) [12] is the tool most commonly used to assess
and quantify beliefs about prescribed medication and
medicines in general. Items from the BMQ are also in-
cluded in the NICE Guidelines as illustrative questions
that could be asked to the patient in a consultation.
The BMQ was originally developed to assess com-
monly held beliefs representative of all illnesses [10, 11],
however many medication regimens are condition-
specific, with LTCs involving a range of different com-
plex and sometimes unique medication challenges. It is
unknown whether the BMQ can capture condition-
specific beliefs. Indeed, the association between medica-
tion beliefs and adherence has not been demonstrated in
all studies, and there are marked differences in effect
sizes [13, 14]. Whilst it is clear that this variation may
reflect differences in clinical populations, the contribu-
tion of other factors that influence adherence, and
differences in the definition and assessment of adherence
[13, 15], one important consideration is whether
condition-specific beliefs are fully captured by existing
BMQ items.
One example of a complex condition associated with
considerable medication challenges is psoriasis, a com-
mon incurable inflammatory skin condition [16] affect-
ing approximately 2-3% of the general population in the
UK [17]. Although psoriasis can occur at any age, the
majority of cases occur before the age of 30 years [18]. It
is generally characterised by well-delineated thick, red
and heavily scaled plaques and people have to manage
considerable psychological and social morbidity [19, 20],
complex medication regimens and adherence difficulties
[21, 22]. Mild, localised disease may be treated with top-
ical therapies (gel, ointment, lotion) by a general practi-
tioner (GP; family doctor), whilst more severe disease
may be managed in specialist dermatology (hospital) set-
tings with phototherapy or photochemotherapy (light
therapy) or traditional systemic (tablets) or biologic ther-
apies (injections) that have immunosuppressant proper-
ties [23]. Typically individuals may move from one
therapeutic approach to another. They may also be
required to cope with concerns about unwanted medica-
tion adverse effects, uncertainty about the degree of dis-
ease control achieved by their medication, unpredictable
relapsing and remitting symptoms, perceptions of incur-
ability, inadequate understanding about the causes of
psoriasis, widespread treatment dissatisfaction and a per-
ceived lack of support from clinicians [24–29]. Un-
like many other LTCs, there is evidence to suggest
that a large proportion of people with psoriasis be-
lieve that their condition is not treated sufficiently
aggressively [26].
In order to improve our understanding of the influ-
ences on medication adherence, the aim of this qualita-
tive study was to examine whether items in the BMQ
are able to fully capture the complexity of condition-
specific medication beliefs, using psoriasis as an exem-
plar of a relapsing-remitting condition where complex
medication challenges are present.
Methods
Participants
Using purposive sampling, people with a diagnosis of
psoriasis who were 18 years or over were recruited from
community venues (e.g. places of worship, libraries,
community halls) and from a national established patient
support association in England. No relationship with
potential participants was established prior to study
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commencement. A participant information pack (PIS)
was sent to 75 potential participants who responded to
the study advertisement, with interested participants
asked to contact the researcher to schedule an interview.
The PIS provided information about the researcher and
the reasons for the study. A separate study (different
research questions and analytic methods) using the same
participant sample has been published [22].
Procedure
Cognitive interviewing (sometimes known as the ‘think-
aloud’ approach) [30–32] is a technique whereby partici-
pants verbalise and report what they are thinking about
as they solve a problem or complete a task, and has been
used to examine the content validity of several question-
naires [33–36]. It can be used to identify how individuals
experience completing a questionnaire and the degree to
which items capture the constructs they purport to
measure, and thus has an important role in the develop-
ment and evaluation of questionnaires alongside other
psychometric assessments.
Using this technique, participants were asked to
‘think-aloud’ and mark their chosen response option for
each item of the BMQ. Participants were instructed to
answer each item in response to their current prescribed
therapy. For those using a combination regimen, partici-
pants were asked to complete the BMQ twice; they
discussed the items in relation to their primary (photo-
therapy/photochemotherapy or systemic therapy) and
secondary therapy (topical therapy) separately. Once
they had completed the BMQ, participants were asked
to suggest any other medication beliefs not included in
the current version of the BMQ. The use of prompts
was limited in order to allow participants to verbalise
their own thought processes, however if it was necessary
to further elucidate any problems or difficulties they
identified when responding to questionnaire items, then
a structured prompt was used (Table 1). Participants
documented their demographic, medication and disease
history before each interview. The recruitment proce-
dures continued until data saturation was reached (no
new themes emerging). Interviews were conducted
during October 2011 and February 2012 at a location
convenient for them; participants were reimbursed for
any travel expenses but were not paid for participation.
Only the participant and the interviewer were present
during interviews; the mean duration was 90-min and
were conducted, audio recorded verbatim and tran-
scribed by one author (R.J.T.). The interviewer was a
health psychology researcher with experience and train-
ing in qualitative methodology. The interpretative com-
ponents were undertaken using secondary validation by
a second author (L.C.). The multidisciplinary research
team (health psychologist, dermatologist, and pharma-
cist), engaged in ongoing discussion to achieve consen-
sus on data coding and to reduce interviewer bias and
assumptions.
Materials
The BMQ [12] is an 18-item measure comprising of two
subscales assessing beliefs about medication as whole,
relating to the nature of medication (general harm) and
beliefs about how they are used by doctors (general over-
use), and two subscales assessing beliefs about medica-
tion prescribed for a specific condition, relating to
perceptions about the personal need for medication (spe-
cific necessity) and concerns about potential negative ef-
fects from medication (specific concerns). The following
are representative items in the BMQ-Specific subscale:
‘My life would be impossible without my psoriasis medi-
cation’ and ‘I sometimes worry about the long-term ef-
fects of my psoriasis medication’. Example items in the
BMQ-General subscale are: ‘Doctors use too many med-
icines’ and ‘People who take medicines should stop their
treatment for a while every now and again’. Satisfactory
reliability and validity coefficients have been reported
[12]. Each item is scored on a 5-point scale, ranging
from ‘strongly disagree’ (=1) to ‘strongly agree’ (=5), with
higher scores indicating stronger medication beliefs. The
BMQ-Specific items were adapted so that the instruc-
tions referred to the participant’s prescribed psoriasis
therapy. One additional item was included in the BMQ
(‘Doctors use too few psoriasis therapies’) to assess
whether participants believe access to psoriasis therapies
is overly-restrictive.
Analysis
Content analysis [37] was used to explore the challenges
of assessing medication beliefs using the BMQ, by
coding the experiences of responding to BMQ items.
The a priori coding framework was based on schedules
used in previous cognitive interview studies [34, 36] and
was applied systematically to the data (Table 2). Data
were analysed in three stages. First, data for each BMQ
domain was analysed separately. Second, data were
coded using the a priori coding framework. Third, data
Table 1 Example structured prompts, adapted from Willis
(2005) [32]
Suggested prompts
•What does that term mean to you as it’s used in the question?
•What were you thinking about when I asked that question?
•How did you come up with that answer?
•How easy or hard was it to determine your answer?
•How did you decide on this answer? How did you decide on this
category response?
•How well does this category response apply to you?
•Does the term used in this question sound OK to you, or would you
use something different?
Thorneloe et al. BMC Health Services Research  (2017) 17:119 Page 3 of 11
were analysed into themes that derived from the data,
with these themes presenting the rationale for the initial
data coding.
Results
A final sample of 20 people demonstrated interest and
agreed to participant in the study, with 14 people re-
cruited from a support website and 6 recruited from the
community (Table 3).
Specific necessity domain
Of the five specific necessity questions, one question
(‘My psoriasis medications protect me from becoming
worse’) did not generate problems relating to item con-
tent (Code 2) and two questions (‘My psoriasis medica-
tions protect me from becoming worse’ and ‘Without
my psoriasis medications I would be very ill’) did not
generate problems relating to misinterpretation (Code
3). The analysis produced four themes for the specific-
necessity domain (Table 4).
Theme 1: Illness identity
Participants viewed psoriasis as being a separate and dis-
tinct entity from their perceptions of disease, with psor-
iasis described as a difficult and distressing ‘condition’,
rather than a life-threatening illness. Participants
objected to some of the terminology used in the specific
necessity scale, in particular the terms ‘health’, ‘ill’ and
‘impossible’, because these terms did not match with
their perceptions of psoriasis.
“I can understand why people would define psoriasis
as an illness, but I suppose I tend to see it more as a
condition.” (P4, specific necessity Q3 ‘Without my
psoriasis medications I would be very ill’, item
response ‘disagree’, score 2/5)
Some participants perceived their psoriasis medication
as ‘necessary’, whilst others viewed medication as having
little impact on physical comfort, psychological and social
well-being. Due to the terminology used in the scale, these
items could under-estimate medication necessity beliefs
as expressed in the interviews, with some participants
choosing to disagree with the specific-necessity state-
ments. Thus, these questions could not differentiate
responses given by individuals who believed that their
psoriasis medication was necessary and those who did not.
“…It can be very sore, it can be very itchy, it can drive
you mad…I would maybe be quite depressed about
Table 2 Item response coding framework
Coding framework
Code 1 Suitable
question
No problems emerged
Code 2 Problematic
item content
Participants identified problems with the
terminology used or questioned the relevance of
the question(s) to psoriasis or medication
Code 3
Misinterpretation
Participants answered a different question from
one that was asked or their verbal responses to
the question did not match the response option
selected
Table 3 Demographic and disease characteristics of participants
Characteristic N
Sex Female 9
Male 11
Ethnicity White 18
Indian 1
Chinese 1
Employment In paid work (full or part-time,
including self-employed)
12
In full-time education/training 3
Unemployed 1
Retired 3
Retired and voluntary work 1
Education 1 or more ‘O’ level equivalents 1
1 or more ‘A’ level equivalents 2
Trade qualifications 3
Professional qualifications 8
Degree 6
Housing Owner occupied/mortgaged 14
Rented from local authority/housing
association
2
Rented from a private landlord 3
Other (living with parents) 1
Psoriasis type Chronic plaque 19
Palmoplantar psoriasis 1
Co-morbid
conditions
Psoriatic arthritis 3
Current therapies*
Topical 16
Phototherapy/photochemotherapy 1
Oral systemic 6
Biologic 1
Non-prescription (e.g. tanning
booths, Chinese medicine)
3
Past therapies*
Topical 18
Phototherapy/photochemotherapy 12
Traditional systemic 7
Median (range)
in years
Age 48.5 (21 – 71)
Age when psoriasis started 14.5 (4 – 52)
Key: * = more than one characteristic can be recorded by each individual
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the whole thing, but I don’t think it would make me
ill” (P14, specific necessity Q3 ‘Without my psoriasis
medications I would be very ill’, item response
‘disagree’, score 2/5)
“My life wouldn’t be impossible, but it would be more
difficult and I would feel socially a lot more
conscious. And I’m sure without them my psoriasis
would be a lot more worse than it is.” (P11, specific
necessity Q2 ‘My life would be impossible without my
psoriasis medications’, item response ‘disagree’, score
2/5)
Theme 2: Illness outcomes
Participants thought that terms used in the BMQ items
such as ‘health’, ‘life’ and ‘ill’ were too broad to capture
the complexity of psoriasis management and questioned
whether the terms were referring to the management of
physical symptoms, psychological or social well-being.
“Well in fairness, do they mean mental health or
physical health…?” (P7, specific necessity Q1 ‘My
health, at present, depends on my psoriasis
medications’, item response ‘disagree’, score 2/5)
Beliefs in whether psoriasis medications helped to
manage physical symptoms or psychological/social well-
being were not necessarily the same, however the BMQ
does not differentiate between these different outcomes.
“…I think that the social impact that the physical
symptoms would give me, as opposed to the physical
symptoms themselves, would make me ill. It would
probably make me very sad, very depressed.” (P11,
specific necessity Q3 ‘Without my psoriasis
medications I would be very ill’, item response
‘uncertain’, score 3/5)
Theme 3: Medication side-effects
Due to the broad terminology used in the specific neces-
sity scale (e.g. the term ‘health’), some participants mis-
interpreted the items about perceived need for psoriasis
therapies for current and future health. Some mistakenly
referred to the impact of potential medication adverse
effects on future health, rather than discussing perceived
need for psoriasis therapies for managing current and
future psoriasis symptoms. This resulted in scores being
an inaccurate representation of their medication neces-
sity beliefs.
“I don’t know whether any of the medications will
have impacted on any of my internal organs.” (P16,
specific necessity Q4 ‘My health in the future will
depend on my psoriasis medications’, item response
‘agree’, score 4/5)
Theme 4: Alternative medications
Many people with psoriasis will use different types of
psoriasis therapy over the course of their condition, due
to inter-individual medication response and changes to
the severity of the condition. Furthermore, medications
can lead to adverse effects and efficacy can diminish
over time, and so they can be administered as combin-
ation, rotation or sequential regimens [38]. As a result,
some participants discussed the possibility of obtaining
alternative psoriasis medications, rather than discussing
their perceptions of current medication necessity. As a
result, scores could again be an inaccurate representa-
tion of medication necessity beliefs.
“I’m uncertain about that, and the reason for that is
because you never know what medications might be
around the corner which might be able to help me.”
(P11, specific necessity Q4 ‘My health in the future
will depend on my psoriasis medications’, item
response ‘uncertain’, score 3/5)
Specific concerns domain
Of the five specific concern questions, one question
(‘Having to take my psoriasis medications worries me’)
did not generate problems relating to item content
(Code 2) and one question (‘I sometimes worry about
the long-term effects of my psoriasis medications’) did
not generate problems relating to misinterpretation
(Code 3). The analysis produced six themes for the
specific concern domain (Table 5).
Theme 5: Terminology
Psoriasis therapies may conflict with patients’ under-
standing of the causes of their psoriasis; indeed, misun-
derstanding regarding the causation of psoriasis has
been reported, including the belief that allergies [18] and
Table 4 Thematic description for the specific necessity domain
Specific necessity domain
Coding
framework
Themes Description
Code 2
Item content
Theme 1 Illness
identity
Mismatch between the
terminology used in the scale and
participants perceptions of their
psoriasis.
Theme 2 Illness
outcomes
Mismatch between the
terminology used in the scale and
participants perceptions of the
complexity of psoriasis
management.
Code 3
Misinterpretation
Theme 3
Medication side-
effects
Participants mistakenly referred to
potential medication adverse
effects.
Theme 4
Alternative
medications
Participants mistakenly referred to
obtaining alternative medications.
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uncontrollable factors (e.g. chance, back luck, poor
medical care in the past, ageing) [39] are possible causal
factors. In order to understand patient’s perceptions of
their medication, assessing whether people understand
why they are prescribed a particular therapy and how
these medications work is necessary. Although item
eight of the BMQ (‘My psoriasis medications are a mys-
tery to me’) attempts to assess perceived understanding,
participants did not understand the term ‘mystery’.
“I don’t understand that [mystery]…I don’t know
quite how to take that” (P17, specific concerns Q8
‘My psoriasis medications are a mystery to me’, item
response ‘uncertain’, score 3/5)
Theme 6: Medication outcomes
Participants expressed the view that some terms used in
the specific concern statements were too broad; partici-
pants differentiated between short- and long-term medi-
cation side-effects, current and future medication
disruptions to daily life, and between physical and
psychological medication dependency. As it currently
stands, the BMQ does not differentiate between these
different outcomes.
“No I never worried about the long-term effects. It
was the short-term effects which bothered me. The fact
that it caused me irritation.” (P9, specific concerns Q7
‘I sometimes worry about the long-term effects of my
psoriasis medications’, item response ‘strongly dis-
agree’, score 1/5)
“I get a bit iffy if I realise that I’ve not got another one
of everything in the house. I once left my wash bag
behind and it had everything in it… my shampoo, my
scalp solution, my creams…two whole days without
anything. So it is like being dependent, but more
mentally dependent on it” (P15, specific concerns
Q10 ‘I sometimes worry about becoming too
dependent on my psoriasis medications’, item
response ‘strongly agree’, score 5/5)
Theme 7: Overly restrictive
A number of participants who were managed by their
GP believed that access to psoriasis medications was
overly restrictive. Existing BMQ items did not assess
these beliefs and thus the inclusion of the condition-
specific item (‘Doctors use too few psoriasis therapies’)
was a useful addition to the BMQ.
“Oh yes, strongly agree [that doctors use too few
treatments]. From my own experience from a number
of G.P’s, I have found that they don’t know what
treatments are available and they seem extraordinarily
reluctant to use any, even if they are aware of them
actually” [P4, over-restrictive belief Q19 ‘Doctors use
too few psoriasis therapies’, item response ‘strongly
agree’, score 5/5]
“Yes I do [agree that doctors use too few treatments].
I mean, they don’t even look into…even with all the
things [therapies] coming out, they cannot be
bothered to give you something else to try.” [P10,
over-restrictive belief Q19 ‘Doctors use too few
psoriasis therapies’, item response ‘agree’, score 4/5]
Theme 8: Failure to reflect the degree of concerns
A number of participants had stopped using their
medication because they were so worried about them.
However participant’s medications concerns were not
Table 5 Thematic description for the specific concerns domain
Specific concerns domain
Coding framework Themes Description
Code 2
Item content
Theme 5 Terminology Participants did not understand the term ‘mystery’.
Theme 6 Medication outcomes Mismatch between the terminology used in the
scale and participants perceptions of the complexity
of medication outcomes.
Theme 7 Overly restrictive Participants believed that access to psoriasis medications
was overly restrictive, with this belief not assessed in
the BMQ.
Code 3
Misinterpretation
Theme 8 Failure to reflect the degree of
concerns
Participants stopped taking their medication because
they were so worried about them. However they stated
that they no longer had concerns because they had
stopped taking their medication.
Theme 9 Illness vs. medications Participants misinterpreted the items and referred to
their psoriasis.
Theme 10 Uncertainty about prescribed
medication
Participants chose the ‘uncertain’ response option to
reflect their own uncertainty about their medication
and how they worked, not uncertainty about their
response.
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identified by the BMQ items, as they felt the statement
no longer applied (that is, “I no longer have concerns
because I have stopped medication”). This resulted in the
underestimation of medication concerns. Those with
very high levels of concern could give low scores, with
these scores incorrectly indicating that they did not have
concerns about the medication.
“You know, I could use it every day for 2 months, but
I don’t. The principle reason, other than it being a
pain, is the long-term effects and skin thinning…”
(P6, specific concerns Q9 ‘My psoriasis medications
disrupt my life’, item response ‘strongly disagree’, score
1/5)
Theme 9: Illness vs. medications
When discussing medication concerns, some partici-
pants discussed their psoriasis rather than their psoriasis
therapies, resulting in scores being an inaccurate repre-
sentation of their concern beliefs.
“I suppose they do really because when it gets bad, I
find it hard to not pick at it and scratch it. And there
are bits of skin all over the place.” (P9, specific
concerns Q9 ‘My psoriasis medications disrupt my
life’, item response ‘agree’, score 4/5)
Theme 10: Uncertainty about prescribed medication
Although expressing worry about potential side-effects,
some participants chose the ‘uncertain’ response option
when answering concern items to reflect their own
uncertainty about their medication and how these medi-
cations worked. This underestimated their medication
concern beliefs.
“…I would probably say uncertain at the moment…
what makes me feel uncertain about it is, you know,
what other side-effects it could pose…could it make
my psoriasis worse if I ever stop taking it…I do worry
whether if I ever stopped the medication, could
something trigger it off to come back much, much
worse than it was before. So that’s a worry.”
[P3, specific concerns Q6 ‘Having to take my psoriasis
medications worries me’, item response ‘uncertain,
score 3/5].
General overuse and harmfulness domains
The analysis produced one theme for the general concern
domains, relating to item misinterpretation.
Theme 11: Medication-specific
Only one item in the general overuse and harmfulness
scales did not generate any problems (‘If doctors had
more time with patients they would prescribe fewer
medicines’). Participants found items in these scales
difficult to answer, as they thought their answer
depended on further information about the medication
that was not specified in the question, such as type of
medication and how it was to be used.
“I’m going to say uncertain about that and again
because it really depends on what type of medicine
you are talking about and what you are using it for.”
[P4, general concerns Q17 ‘Most medicines do more
harm than good’, item response ‘uncertain’, score 3/5]
Discussion
This qualitative study examined the extent to which the
BMQ is suitable for assessing condition-specific medica-
tion beliefs, using psoriasis as a suitable exemplar of a
complex condition characterised by relapsing-remitting
symptoms and considerable medication challenges. Psor-
iasis was a useful condition to choose as its treatment
includes a range of therapeutic approaches including
different mechanisms. Its treatment pathway shares a
great deal with other inflammatory conditions such as
rheumatoid arthritis, inflammatory bowel disease as well
as other long-term dermatological conditions. This work
has important implications for the use of the BMQ in
research and clinical settings.
Personal model of psoriasis and medication
Individuals’ perceptions of their psoriasis and medication
influenced the extent to which the BMQ items were able
to capture the aspects of the constructs they were de-
signed to measure. Consistent with previous research
[28, 29], psoriasis was viewed as a condition that was
separate from perceptions of illness and disease, with a
wide impact on functioning and complex medication
outcomes. Due to the mismatch between the termin-
ology used in the scale and individuals perceptions of
psoriasis, the existing BMQ items led to scores that
underestimated levels of medication necessity beliefs.
Furthermore, the existing BMQ items were too broad to
capture the complexity of participants’ perceptions of
psoriasis management and medication outcomes, result-
ing in scores being an inaccurate representation of medi-
cation necessity beliefs.
Misinterpretation
Many of the misinterpretation problems identified in
this study are parallel to those reported in other LTCs
with different psychometric tools [33–36], with partici-
pants experiencing difficulty in generating an answer or
answering different questions from what was asked.
However a crucial key discovery was that the levels of
medication concerns held by participants were signifi-
cantly underestimated when assessed using the BMQ.
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Although some participants had stopped taking their
prescribed psoriasis therapy because of their concerns
about its usage, they believed the concern statements no
longer applied because they were no longer using the
medication.
Some BMQ items did not generate any problems with
item content and/or misinterpretation, whilst others
produced multiple problems. It was not the aim at this
stage to provide a quantitative assessment of the number
of problems generated for each individual item, but to
identify general and condition-specific difficulties experi-
enced by individuals when completing the BMQ. Indeed,
it is clear that many of the problems were applicable to
all items within each BMQ domain.
Medication adherence and supporting shared decision-
making
The introduction of the Necessity-Concerns Framework
by Horne and colleagues has changed our understanding
of the role of medication beliefs in medication adher-
ence. However there are differences in effect sizes in the
association between medication beliefs and adherence,
with some studies reporting no association [13, 14].
Whilst the BMQ has been a major contribution to the
assessment of medication beliefs, this study has identi-
fied limitations of its use in complex LTCs. There is in-
creasing recognition that we need to increase the
specificity of measurement tools for the condition, for
example, the authors of the tool most commonly used to
assess illness beliefs, the Illness Perception Questionnaire-
Revised [40], encourage the adaptation of the scale to dif-
ferent condition- or disease contexts. This approach can
only help improve the validity of the core tools needed to
assess predictors of adherence behaviours. Future work
should examine the suitability of the BMQ in other
chronic illness populations, as many of the problems iden-
tified in this study are applicable to other illness groups.
Many patients perceive healthcare professionals, espe-
cially GP’s, as lacking expertise, empathy and under-
standing in managing psoriasis, with some patients with
poorly controlled psoriasis finding it difficult to obtain a
specialist dermatology referral from their GP and some
withdrawing from healthcare professional support [28,
29]. In addition, there is evidence to suggest that a large
proportion of people with psoriasis believe that their
condition is not treated sufficiently aggressively [26].
This study has taken this further by demonstrating that
participants who were being managed by their GP
expressed strong beliefs that access to psoriasis medica-
tions is overly restrictive. An important area for future
investigation is to assess the relationship between these
illness-specific beliefs with medication adherence; for in-
dividuals who are being managed in primary care with
topical therapies, individuals may underuse their topical
medication in order to be referred to specialist care for
systemic therapies. Alternatively, individuals may overuse
their topical medication in an attempt to manage uncer-
tain topical medication efficacy and gain control over
the problematic control of symptoms. A belief that med-
ications are overused is a common concern [41] and
captured in the BMQ (General-overuse subscale). The
addition of a subscale representing beliefs in the overly
restrictive access to medication is required if researchers
and clinicians are to be able to identify the full range of
beliefs that influence medicines adherence.
In the UK NICE Medicines Adherence Guidelines [7],
there is strong emphasis on the need to explore patients’
perspectives of medicines, to encourage patients to dis-
cuss any doubts or concerns they have about their medi-
cation and whether they believe they need them, in
order to help ensure that people actively participate in
decision-making and to support optimal self-
management. Patients do not openly disclose their be-
liefs to clinicians [42], through fear of being labelled a
‘bad patient’, undeserving, and through fear of potential
negative consequences (e.g. being taken off their treat-
ment). Self-report tools may provide a valuable aid for
clinicians in helping to elicit patients’ perceptions of
their medication. We have demonstrated the challenges
of assessing medication beliefs in a common and com-
plex LTC, including the need to ensure that tool items
are able to represent condition-specific beliefs and are
clear to the individual in order to prevent item
misinterpretation.
Strengths and limitations
We acknowledge that the total number of participants
was small, with the majority recruited through support
groups, and thus the findings may only be generalisable
to this group. However recruitment from non-clinical
settings resulted in a diverse sample ranging in disease
and treatment history, including those who have disen-
gaged from conventional health services. The nature of
recruitment precludes assessment of the reasons given
for non-participation. Although participants were not in-
volved in the design of this study, all participants were
fully briefed on its aims, interpretation and implications.
Due to the nature of the study, participants did not
check the transcripts. This is because participants may
have requested to change their ‘real time’ response if, for
example, they initially misinterpreted the items. Asking
participants using combination therapy to complete the
BMQ twice may have increased the cognitive complexity
of the task. Although we acknowledge this limitation, it
realistically reflects the inherent challenges of measuring
medication beliefs in individuals managing complex
LTCs and polypharmacy. Our results are broadly consist-
ent with other think-aloud studies using different
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psychometric tools and clinical populations [33–36],
with the sample size similar to other think-aloud studies
[34, 36]. Although the think-aloud method has provided a
valuable technique for revealing the challenges of assessing
complex medication beliefs, future studies should develop
this tool using additional psychometric evaluations.
This is the first study to explore the complexity of
assessing medication beliefs in ‘real time’. The Necessity-
Concerns Framework continues to have a pivotal role in
furthering our understanding of medication adherence,
however this study has identified problems with the items
intended to measure is central constructs. We recom-
mend that the BMQ is adapted by researchers for disease
or medication specific use, perhaps by using real-time
assessments of participants’ responses. The current study
has emphasised the importance of adapting the BMQ to
represent condition-specific medication beliefs, including
focusing on the terminology used to describe the
condition under investigation, considering the complexity
of illness outcomes, and the need to identify additional
condition-specific medication beliefs, such as beliefs in
overly restrictive access to medications. It is also necessary
to ensure that the statements are unambiguous to partici-
pants in order to prevent item misinterpretation, which
may include terminology changes, providing clarifying
statements, or changing item response choices. Suggested
condition-specific and general changes are presented
in Table 6.
Conclusions
Using psoriasis as a suitable exemplar of a complex
condition associated with considerable medication chal-
lenges, this study has identified general and condition-
specific difficulties experienced by individuals completing
the BMQ in ‘real time’. Medication beliefs were underesti-
mated, or not fully captured, by existing BMQ items. In
order to improve our understanding of medication adher-
ence and help support shared decision-making, the results
from this study should be used as a basis in the develop-
ment of condition-specific BMQ items, for use in both a
research and clinical setting.
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Table 6 Condition-specific and general changes for the BMQ
Item content Condition-specific changes General changes to instructions/terminology
Specific
necessity
Ensure that terminology used to describe the condition
maps onto participants’ perceptions of their condition.
A clarifying statement should precede specific necessity items. E.g.
‘Please refer to your personal views about the impact of the medicines
on your overall future health, not the impact of potential medication
side-effects on future health’
Need to differentiate between the impact of medication
on physical symptoms and psychological/social well-being
A clarifying statement should precede specific necessity items. E.g. ‘You
may be using a different medication in the future. However please refer
to your personal views about the medication currently prescribed for you’
Specific
concerns
Need to differentiate between:
1.Short- and long-term medication side-effects
2.Current and future medication disruptions to daily life
3.Physical and psychological medication dependency
A clarifying statement should precede specific concern items. E.g.
‘Some people choose not to use their medication as prescribed.
However please imagine that you are using your medication as
prescribed and indicate whether this would make you experience feelings
of worry’
Identify additional condition-specific beliefs (e.g. overly
restrictive access to medications)
A clarifying statement should precede specific concern items. E.g.
‘Please refer to your personal views about your medicines, not your
condition’
The specific concern item ‘My psoriasis medications are a mystery to
me’ should be rephrased. E.g. ‘I sometimes experience uncertainty
about my medicines and how they work’
General
concerns
Ensure the phrase ‘in general’ precedes each item. E.g. ‘In general,
doctors use too many medicines’
Item
response choice
Condition-specific changes General changes to instructions/terminology
All BMQ
domains
For all BMQ items, the item response choice ‘uncertain’ should be
changed to ‘don’t know’
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